US Food and Drug Administration (FDA) has approved mNEXSPIKE (mRNA-1283), a new vaccine against Covid-19, for use in all adults 65 and older, as well as individuals aged 12-64 years with at least one ...

Investor sentiment toward Moderna Inc. turned sour during the weekend, despite obtaining FDA authorization for its newest ...

The Food and Drug Administration has approved Moderna's new COVID-19 vaccine, days after the federal government tightened ...

Can the American people (or some other entity) sue RFK Jr for the harm he is no doubt causing us? What he is doing is so ...

The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...

Several mRNA vaccine trials found a debilitating side effect, and now the Trump administration is cutting funding for more ...

The shot, dubbed mNexspike, is approved for older adults and people whose health conditions put them at higher risk of severe ...

The FDA has approved Moderna’s new Covid-19 vaccine, though it placed restrictions on its use that the company’s existing ...

Moderna (MRNA) stock in focus as the U.S. FDA approved its next-gen COVID-19 vaccine, mNEXSPIKE,. Read more here.

The FDA approved Novavax’s COVID vaccine Nuvaxovid this month, limiting its use to older adults and people over the age of 12 with conditions that put them at risk due to the illness.

NEXSPIKE becomes Moderna’s third FDA-approved product CAMBRIDGE, MA / ACCESS Newswire / May 31, 2025 / Moderna, Inc.